Skip to content

Organon OGN Accrued Litigation

Accrued Litigation at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$70.02M-4.1%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
Viatris logo
ViatrisVTRS
Bausch + Lomb logo
Bausch + LombBLCO

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserve.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's accrued litigation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's accrued litigation?
Organon (OGN) reported accrued litigation of $9M in Q1 2026.
How has Organon's accrued litigation changed year-over-year?
Organon's accrued litigation decreased by 10.0% year-over-year, from $10M to $9M.
What is the long-term trend for Organon's accrued litigation?
Over 5 years (2020 to 2025), Organon's accrued litigation has grown at a -22.2% compound annual growth rate (CAGR), from $35M to $10M.